Knowing if a patient with stable disease will ultimately do well on their treatment is challenging. Using serial images, our CT Response Score outperformed traditional methods in early assessment of immunotherapy outcomes for NSCLC patients. Details presented at the 2024 SITC annual meeting. #OncAI #Immunotherapy #LungCancer #AIinHealthcare #DigitalHealth #SITC #PrecisionOncology
Onc.AI
Software Development
San Carlos, CA 1,249 followers
Non-invasive radiomic-based biomarkers for clinical decision support
About us
Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.
- Website
-
http://www.onc.ai
External link for Onc.AI
- Industry
- Software Development
- Company size
- 11-50 employees
- Headquarters
- San Carlos, CA
- Type
- Privately Held
- Founded
- 2020
- Specialties
- AI, Genomics, Oncology, Radiomics, ML, Diagnostics, Personalized Medicine, and Immunotherapy
Locations
-
Primary
Get directions
San Carlos, CA 94070, US
-
Get directions
Waterloo, Canada, CA
Employees at Onc.AI
Updates
-
We are excited and welcome this important collaboration with National Cancer Institute (NCI) #SBIR which will advance our radiomics deep learning clinical decision support solution for metastatic NSCLC. https://lnkd.in/gwUwXayr
Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC
businesswire.com
-
Onc.AI reposted this
Great discussion with our CEO Akshay Nanduri and Tina Wang from DeciBio on the power of radiomics to support biopharma clinical development! Read more below!! #radiomics #onc.ai #NSCLC #asco2024 #personalizedMedicine #immunotherapy
Radiomics is gaining momentum as a transformative tool in medical research and clinical practice. In this latest Q&A, Onc.AI CEO Akshay Nanduri shares insights on the advancements pushing radiomics from research to clinical application. Explore how AI-driven innovations are reshaping oncology and beyond in our newest blog: 'Radiomics: The Intersection of Modern Deep Learning and Clinical Imaging.' https://lnkd.in/gjDhKDJm This kicks off Tina Wang ongoing series on #radiomics, with this blog co-authored by Benjamin Zaidel. Stay tuned for more interviews highlighting the latest breakthroughs in the field.
-
-
Great discussion with our CEO Akshay Nanduri and Tina Wang from DeciBio on the power of radiomics to support biopharma clinical development! Read more below!! #radiomics #onc.ai #NSCLC #asco2024 #personalizedMedicine #immunotherapy
Radiomics is gaining momentum as a transformative tool in medical research and clinical practice. In this latest Q&A, Onc.AI CEO Akshay Nanduri shares insights on the advancements pushing radiomics from research to clinical application. Explore how AI-driven innovations are reshaping oncology and beyond in our newest blog: 'Radiomics: The Intersection of Modern Deep Learning and Clinical Imaging.' https://lnkd.in/gjDhKDJm This kicks off Tina Wang ongoing series on #radiomics, with this blog co-authored by Benjamin Zaidel. Stay tuned for more interviews highlighting the latest breakthroughs in the field.
-
-
Onc.AI reposted this
Accurate identification of patients likely to respond to single-agent immunotherapy can be challenging despite the availability of traditional biomarkers, see how our non-invasive radiomic-based approach offers an alternative approach to enhance patient selection. #asco24 #precisionmedicine #personalized #radiomics #oncology #NSCLC #immunotherapy
Onc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung Cancer
businesswire.com
-
Onc.AI reposted this
Accurate identification of patients likely to respond to single-agent immunotherapy can be challenging despite the availability of traditional biomarkers, see how our non-invasive radiomic-based approach offers an alternative approach to enhance patient selection. #asco24 #precisionmedicine #personalized #radiomics #oncology #NSCLC #immunotherapy
Onc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung Cancer
businesswire.com
-
Accurate identification of patients likely to respond to single-agent immunotherapy can be challenging despite the availability of traditional biomarkers, see how our non-invasive radiomic-based approach offers an alternative approach to enhance patient selection. #asco24 #precisionmedicine #personalized #radiomics #oncology #NSCLC #immunotherapy
Onc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung Cancer
businesswire.com
-
Our research on radiomic biomarkers for predicting NSCLC treatment outcomes has been accepted for an oral presentation at this year’s ASCO Annual Meeting! Contact us to find out more Onc.AI #ASCO24 #Oncology #Radiomics #PrecisionMedicine #PersonalizedMedicine #Immunotherapy #NSCLC
-
-
We're absolutely thrilled to announce Kevin Masukawa Ph.D. has been appointed Chief Commercial Officer at Onc.AI -- where he'll lead Sales, Marketing and Market-Access organizations. Kevin brings significant oncology sales and strategic marketing experience with past tenures at L.E.K, Genentech (12+ years) and most recently as VP Oncology Marketing at Natera where he architected and executed the market adoption strategy for the breakthrough Signatera test for Molecular Residual Disease (MRD) in solid tumors. Kevin holds a PhD in Chemical Biology from UCSF and BSc in Biochemistry from UCSD.